The FDA said on Tuesday that it was adding new warning to the labels of diabetes drugs containing the saxagliptin and alogliptin. The FDA said the drugs “may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.” The announcement comes two years after an FDA panel recommended that…
FDA Adds Heart Failure Warning To Saxagliptin and Alogliptin Labels
April 6, 2016 by Leave a Comment
Heart Failure: The Missing 800 Pound Gorilla In Diabetes Trials
March 12, 2014 by Leave a Comment
Is heart failure the missing 800 pound gorilla in diabetes trials? That’s the argument proposed by a group of prominent cardiovascular and diabetes researchers. It was long believed that by virtue of their glucose-lowering properties diabetes drugs would confer substantial cardiovascular benefits. Now, however, that belief is no longer widely held and the FDA now…
Linagliptin And Glimepiride Compared In Type Two Diabetes
June 29, 2012 by Leave a Comment
Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients with type 2 diabetes taking metformin were randomized to the addition of either linagliptin, a dipeptidyl peptidase-4 inhibitor or the sulfonylurea glimepiride. After two years…
Transient Glucose Regulation Helps Prevent Progression To Diabetes In Prediabetics
June 9, 2012 by Leave a Comment
Prediabetics– people with impaired fasting glucose or impaired glucose tolerance– can reduce their high risk of progressing to diabetes if they achieve even a transient return to normal glucose regulation, according to results of the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association meeting and published simultaneously online in the Lancet. Leigh…
Recent Comments